Chinese expert consensus on perioperative management of patients with resectable anaplastic lymphoma kinase-fusion non–small cell lung cancer

IF 4.4 2区医学 Q1 ONCOLOGY

Lung Cancer Pub Date : 2025-08-21 DOI:10.1016/j.lungcan.2025.108716

Hai-Yan Tu , Chun Chen , Chang Chen , Chao Cheng , Ying Cheng , Junke Fu , Feng Jiang , Gaofeng Li , Yongde Liao , Jiwei Liu , Shun Lu , Wei-Min Mao , Pingping Song , Yong Song , Qun Wang , Fan Yang , Yi Yang , Jianming Ying , Jun Zhao , Wen-Zhao Zhong , Yi-Long Wu

{"title":"Chinese expert consensus on perioperative management of patients with resectable anaplastic lymphoma kinase-fusion non–small cell lung cancer","authors":"Hai-Yan Tu , Chun Chen , Chang Chen , Chao Cheng , Ying Cheng , Junke Fu , Feng Jiang , Gaofeng Li , Yongde Liao , Jiwei Liu , Shun Lu , Wei-Min Mao , Pingping Song , Yong Song , Qun Wang , Fan Yang , Yi Yang , Jianming Ying , Jun Zhao , Wen-Zhao Zhong , Yi-Long Wu","doi":"10.1016/j.lungcan.2025.108716","DOIUrl":null,"url":null,"abstract":"<div><div>This Chinese expert consensus addresses comprehensive recommendations on biomarker testing, treatment, and follow-up in the perioperative management of patients with resectable ALK-fusion non-small cell lung cancer (NSCLC). The document highlights the pivotal role of cancer genomic testing in informing personalized therapeutic decision-making. The application of perioperative targeted therapies, including alectinib, has demonstrated significant potential in improving clinical outcomes for patients with ALK-fusion NSCLC. The consensus further underscores the necessity for expanded clinical research and trials to optimize and validate individualized treatment strategies, thereby advancing the standard of care in this patient population.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"208 ","pages":"Article 108716"},"PeriodicalIF":4.4000,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0169500225006087","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

This Chinese expert consensus addresses comprehensive recommendations on biomarker testing, treatment, and follow-up in the perioperative management of patients with resectable ALK-fusion non-small cell lung cancer (NSCLC). The document highlights the pivotal role of cancer genomic testing in informing personalized therapeutic decision-making. The application of perioperative targeted therapies, including alectinib, has demonstrated significant potential in improving clinical outcomes for patients with ALK-fusion NSCLC. The consensus further underscores the necessity for expanded clinical research and trials to optimize and validate individualized treatment strategies, thereby advancing the standard of care in this patient population.

查看原文本刊更多论文

可切除间变性淋巴瘤激酶融合非小细胞肺癌围手术期处理的专家共识

本中国专家共识针对可切除alk融合非小细胞肺癌（NSCLC）患者围手术期管理的生物标志物检测、治疗和随访提出了综合建议。该文件强调了癌症基因组检测在为个性化治疗决策提供信息方面的关键作用。围手术期靶向治疗的应用，包括alectinib，已经证明在改善alk融合NSCLC患者的临床结果方面具有显著的潜力。共识进一步强调了扩大临床研究和试验的必要性，以优化和验证个体化治疗策略，从而提高这一患者群体的护理标准。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Lung Cancer 医学-呼吸系统

CiteScore

9.40

自引率

3.80%

发文量

407

审稿时长

25 days

期刊介绍： Lung Cancer is an international publication covering the clinical, translational and basic science of malignancies of the lung and chest region.Original research articles, early reports, review articles, editorials and correspondence covering the prevention, epidemiology and etiology, basic biology, pathology, clinical assessment, surgery, chemotherapy, radiotherapy, combined treatment modalities, other treatment modalities and outcomes of lung cancer are welcome.